Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 264 articles:
HTML format



Single Articles


    October 2024
  1. GONZALEZ-SAN SEGUNDO C, Lopez Campos F, Gomez Iturriaga A, Rodriguez A, et al
    A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
    BJU Int. 2024;134:568-577.
    PubMed     Abstract available


  2. KINNEAR N, Fonseca PC, Ogbechie C, Adam S, et al
    Impact of frozen section on long-term outcomes in robot-assisted laparoscopic prostatectomy.
    BJU Int. 2024;134:608-614.
    PubMed     Abstract available


  3. TAYA M, Behr SC, Westphalen AC
    Perspectives on technology: Prostate Imaging-Reporting and Data System (PI-RADS) interobserver variability.
    BJU Int. 2024;134:510-518.
    PubMed     Abstract available


  4. SAHNI DS, Morrison J, Leung HY
    Grid-based cognitive diagnostic prostatic biopsy without transrectal ultrasonography.
    BJU Int. 2024;134:659-663.
    PubMed    


    September 2024
  5. FANG AM, Gregg JR, Pettaway C, Ma J, et al
    Whole-body MRI for staging prostate cancer: a narrative review.
    BJU Int. 2024 Sep 22. doi: 10.1111/bju.16514.
    PubMed     Abstract available



  6. Advances in the detection and treatment of prostate cancer plus d-mannose for the prevention of recurrent UTIs.
    BJU Int. 2024;134:321-322.
    PubMed    


  7. REIJNDERS-BOERBOOM GTJA, Jacobs LMC, Helder LS, Panhuizen IF, et al
    Recovery and immune function after low pressure pneumoperitoneum during robot-assisted radical prostatectomy: a randomised controlled trial.
    BJU Int. 2024;134:416-425.
    PubMed     Abstract available


  8. TOUZANI A, D'Agate D, Kesch C, Calleris G, et al
    One-year outcomes of same-day-discharge robot-assisted radical prostatectomy.
    BJU Int. 2024;134:380-382.
    PubMed    


  9. OUCHI M, Kitta T, Chiba H, Higuchi M, et al
    Physiotherapy for continence and muscle function in prostatectomy: a randomised controlled trial.
    BJU Int. 2024;134:398-406.
    PubMed     Abstract available


  10. BATES AS, Sharma AD, Camilleri P, Browning L, et al
    'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.
    BJU Int. 2024;134:377-379.
    PubMed    


    August 2024
  11. TAKAHASHI T
    Observational study on screen-detected prostate cancer: case series of empirical clinical practice.
    BJU Int. 2024 Aug 29. doi: 10.1111/bju.16525.
    PubMed    


  12. ONG WL, Krishnaprasad K, Bensley J, Steeper M, et al
    Population-based prostate cancer outcomes registries - what have we learned and where are we heading?
    BJU Int. 2024 Aug 19. doi: 10.1111/bju.16487.
    PubMed    


  13. GEBOERS B, Scheltema MJ, Jung J, Bakker J, et al
    Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.
    BJU Int. 2024 Aug 5. doi: 10.1111/bju.16496.
    PubMed     Abstract available


  14. JACEWICZ M, Rud E, Lauritzen P, Baco E, et al
    Non-infectious adverse events of transperineal prostate biopsies performed under local anaesthesia.
    BJU Int. 2024;134:300-306.
    PubMed     Abstract available


  15. FANKHAUSER CD, Malkmus C, Aschwanden F, Baumeister P, et al
    'Igloo' technique for robot-assisted radical prostatectomy - maximum nerve sparing for early recovery of continence and sexual function.
    BJU Int. 2024;134:307-311.
    PubMed    


  16. ABUELNAGA M, Gendy R, Yao M, Phelan C, et al
    Impact of definitions on continence outcomes in a series of 1000 robot-assisted radical prostatectomies, time for an internationally agreed definition?
    BJU Int. 2024;134:197-200.
    PubMed    


  17. NG KL, Giona S, Barber N
    Feasibility of Aquablation prostate surgery performed as day cases.
    BJU Int. 2024;134:185-186.
    PubMed    


    July 2024
  18. BANCROFT EK
    Response to BJU-2024-0780: RE: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    BJU Int. 2024 Jul 26. doi: 10.1111/bju.16490.
    PubMed    


  19. DAUNGSUPAWONG H, Wiwanitkit V
    RE: 'The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers'.
    BJU Int. 2024 Jul 26. doi: 10.1111/bju.16489.
    PubMed    


  20. YANG J, Xiong X, Wei Q, Yang L, et al
    Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer.
    BJU Int. 2024 Jul 17. doi: 10.1111/bju.16467.
    PubMed    


  21. MAURER J, Ambrosini F, Chen Y, Schroeder S, et al
    Acupuncture: a strategy for pain management among patients with prostate cancer - authors' reply.
    BJU Int. 2024 Jul 16. doi: 10.1111/bju.16468.
    PubMed    


  22. SCHMIDT B, Soerensen SJC, Bhambhvani HP, Fan RE, et al
    External validation of an artificial intelligence model for Gleason grading of prostate cancer on prostatectomy specimens.
    BJU Int. 2024 Jul 11. doi: 10.1111/bju.16464.
    PubMed     Abstract available


  23. WENZEL M, Hoeh B, Koll F, Humke C, et al
    Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
    BJU Int. 2024 Jul 10. doi: 10.1111/bju.16462.
    PubMed     Abstract available


  24. ARVIDSSON I, Svanemur E, Marginean F, Simoulis A, et al
    Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.
    BJU Int. 2024 Jul 4. doi: 10.1111/bju.16456.
    PubMed     Abstract available



  25. Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
    BJU Int. 2024;134:4-5.
    PubMed    


  26. JUSSILA I, Ahtiainen JP, Laakkonen EK, Siltari A, et al
    Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol.
    BJU Int. 2024;134:110-118.
    PubMed     Abstract available


  27. SOPUTRO NA, Chavali JS, Ferguson EL, Ramos-Carpinteyro R, et al
    Complications of single-port robot-assisted radical prostatectomy: multi-institutional analysis from the Single-Port Advanced Research Consortium (SPARC).
    BJU Int. 2024;134:54-62.
    PubMed     Abstract available


  28. MORETTI TBC, Magna LA, Reis LO
    Continence criteria of 193 618 patients after open, laparoscopic, and robot-assisted radical prostatectomy.
    BJU Int. 2024;134:13-21.
    PubMed     Abstract available


    June 2024
  29. KATO T, Matsumoto R, Yokomizo A, Tohi Y, et al
    Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
    BJU Int. 2024 Jun 17. doi: 10.1111/bju.16436.
    PubMed     Abstract available


  30. BANCROFT EK, Page EC, Brook MN, Pope J, et al
    The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    BJU Int. 2024 Jun 5. doi: 10.1111/bju.16432.
    PubMed     Abstract available


  31. HAHN AW, Manyam GC, Chapin BF, Zhang M, et al
    A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
    BJU Int. 2024 Jun 4. doi: 10.1111/bju.16414.
    PubMed     Abstract available



  32. Prostate cancer: To screen, or not to screen? That is the question.
    BJU Int. 2024;133:635-637.
    PubMed    


  33. FRANCO A, Ditonno F, Manfredi C, Licari LC, et al
    Robot-assisted single-port transvesical enucleation of the prostate: step-by-step technique and early single-centre experience.
    BJU Int. 2024;133:778-782.
    PubMed    


  34. NOLSOE AB, Ostergren PB, Jakobsen H, Jensen CFS, et al
    Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial.
    BJU Int. 2024;133:742-751.
    PubMed     Abstract available


  35. MAURER J, Friedemann T, Chen Y, Ambrosini F, et al
    A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy.
    BJU Int. 2024;133:725-732.
    PubMed     Abstract available


  36. LENFANT L, Beitone C, Troccaz J, Roupret M, et al
    Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation.
    BJU Int. 2024;133:709-716.
    PubMed     Abstract available


  37. ALMEIDA-MAGANA R, Au M, Al-Hammouri T, Dinneen K, et al
    Improving fluorescence confocal microscopy for margin assessment during robot-assisted radical prostatectomy: The LaserSAFE technique.
    BJU Int. 2024;133:677-679.
    PubMed    


  38. MAC CURTAIN BM, Sugrue DD, Qian W, O'Callaghan M, et al
    Membranous urethral length and urinary incontinence following robot-assisted radical prostatectomy: a systematic review and meta-analysis.
    BJU Int. 2024;133:646-655.
    PubMed     Abstract available


    May 2024
  39. GALIETTA E, Strolin S, Lodi-Rizzini E, Castellucci P, et al
    Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer.
    BJU Int. 2024 May 22. doi: 10.1111/bju.16399.
    PubMed    


  40. PELTIER A, van Velthoven R, Baudewyns A, Assenmacher G, et al
    Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study.
    BJU Int. 2024 May 14. doi: 10.1111/bju.16385.
    PubMed     Abstract available


  41. BENJAMIN DJ, Yazdanpanah O, Rezazadeh Kalebasty A
    A review of vitamin use for the prevention or treatment of prostate cancer.
    BJU Int. 2024 May 13. doi: 10.1111/bju.16398.
    PubMed    


  42. PASANEN N, Talala K, Remmers S, Tammela TLJ, et al
    Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
    BJU Int. 2024 May 9. doi: 10.1111/bju.16394.
    PubMed     Abstract available


  43. GRAJALES V, Martini A, Shore ND
    Complications of immuno-oncology care: what urologist should know.
    BJU Int. 2024;133:524-531.
    PubMed     Abstract available


  44. CHALOUPKA M, Pyrgidis N, Ebner B, Volz Y, et al
    Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
    BJU Int. 2024;133:548-554.
    PubMed     Abstract available


    April 2024
  45. SIMHAL RK, Wang KR, Shah YB, Lallas CD, et al
    Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer.
    BJU Int. 2024 Apr 23. doi: 10.1111/bju.16370.
    PubMed     Abstract available


  46. STATTIN P, Fleming S, Lin X, Lefresne F, et al
    Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16362.
    PubMed     Abstract available


  47. RODRIGUEZ-SANCHEZ L, Reiter R, Rodriguez A, Emberton M, et al
    The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer.
    BJU Int. 2024 Apr 13. doi: 10.1111/bju.16360.
    PubMed    


  48. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
    Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
    BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
    PubMed     Abstract available


  49. VICKERS A
    Magnetic resonance imaging-targeted prostate biopsy changed everything (so everything has to change).
    BJU Int. 2024;133:354-355.
    PubMed    


  50. MCNICHOLAS DP, Parr NJ
    Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
    BJU Int. 2024;133:487-490.
    PubMed     Abstract available


  51. JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
    Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk of overtreatment in prostate cancer: a grading issue.
    BJU Int. 2024;133:432-441.
    PubMed     Abstract available


  52. MEHAWED G, Murray R, Rukin NJ, Roberts MJ, et al
    Prostate tumour visualisation with PET: is image fusion with MRI the answer?
    BJU Int. 2024;133 Suppl 4:4-6.
    PubMed    


    March 2024
  53. ALBERTSEN PC
    Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
    BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
    PubMed    


  54. TAKAHASHI T
    Endpoint and control group in prostate cancer screening research: public health basics.
    BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
    PubMed    


  55. PAK JS, Huang R, Huang WC, Lepor H, et al
    Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
    BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
    PubMed     Abstract available


  56. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
    PubMed    


  57. HAMDY FC, Albertsen PC, Donovan JL
    Screening and active surveillance in prostate cancer: the dilemma continues.
    BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
    PubMed    


  58. HUBER J, Karschuck P, Valdix J, Thomas C, et al
    Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
    PubMed     Abstract available


  59. TAKAHASHI T
    Active surveillance in all cases of screen-detected prostate cancer.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
    PubMed    


  60. ROKAN N, Reddy D, Dudderidge T
    Focal therapy for prostate cancer - when to refer?
    BJU Int. 2024 Mar 13. doi: 10.1111/bju.16315.
    PubMed    


  61. VAN HARTEN MJ, Roobol MJ, van Leeuwen PJ, Willemse PM, et al
    Evolution of European prostate cancer screening protocols and summary of ongoing trials.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16311.
    PubMed     Abstract available


  62. LOFFELER S, Bertilsson H, Muller C, Aas K, et al
    Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged >/=75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16314.
    PubMed     Abstract available


  63. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
    Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
    BJU Int. 2024;133:324-331.
    PubMed     Abstract available


    February 2024
  64. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
    Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
    PubMed    


  65. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
    During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
    BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
    PubMed     Abstract available


  66. ZUUR LG, de Barros HA, van Oosterom MN, Berrens AC, et al
    (99m) TcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial.
    BJU Int. 2024 Feb 12. doi: 10.1111/bju.16297.
    PubMed     Abstract available


  67. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
    Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
    BJU Int. 2024;133:197-205.
    PubMed     Abstract available


  68. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
    International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
    BJU Int. 2024;133:179-187.
    PubMed     Abstract available


  69. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
    How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
    BJU Int. 2024;133 Suppl 3:13-14.
    PubMed    


  70. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
    The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    BJU Int. 2024;133 Suppl 3:39-47.
    PubMed     Abstract available


    January 2024
  71. SANCHEZ-SALAS R
    Candid choices: optimising patient selection in prostate cancer focal therapy.
    BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
    PubMed    


  72. BESIROGLU H
    Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
    PubMed    


  73. TALWAR R, Akinsola O, Penson DF
    What is cancer? A focus on Grade Group 1 prostate cancer.
    BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
    PubMed     Abstract available


  74. ALBERTSEN PC, Bjerner LJ, Pasovic L, Muller S, et al
    Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
    BJU Int. 2024;133:104-111.
    PubMed     Abstract available


  75. MAYOR N, Eldred-Evans D, Tam H, Sokhi H, et al
    Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
    BJU Int. 2024;133:112-117.
    PubMed     Abstract available


    December 2023
  76. GUERCIO A, Franco G, Lombardo R, De Nunzio C, et al
    LETTER TO THE EDITOR Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16263.
    PubMed    


  77. LENI R, Roscigno M, Barzaghi P, La Croce G, et al
    Medium-term follow up of active surveillance for early prostate cancer at a non-academic institution.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16259.
    PubMed     Abstract available


    November 2023
  78. GABRIEL J, Gabriel A, Shafik L, Alanbuki A, et al
    AI in the urology MDM: can ChatGPT suggest EAU guideline-recommended prostate cancer treatments?
    BJU Int. 2023 Nov 27. doi: 10.1111/bju.16240.
    PubMed    


  79. SHANMUGASUNDARAM R, Saad J, Heyworth A, Wong V, et al
    Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    BJU Int. 2023 Nov 9. doi: 10.1111/bju.16115.
    PubMed     Abstract available


    October 2023
  80. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
    CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
    PubMed     Abstract available


  81. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
    Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
    BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
    PubMed     Abstract available


  82. GEBOERS B, Meijer D, Counter W, Blazevski A, et al
    PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16207.
    PubMed     Abstract available


  83. TISSOT S, Wynn J, Tran V, Farag M, et al
    Re-defining (18) F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology.
    BJU Int. 2023;132:411-419.
    PubMed     Abstract available


  84. BOEVE LMS, Bloemendal FT, de Bie KCC, van Haarst EP, et al
    Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated.
    BJU Int. 2023;132:397-403.
    PubMed     Abstract available


    September 2023
  85. LEHNER F, Crippa A, Sigg S, Eberli D, et al
    Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16181.
    PubMed     Abstract available


  86. JALLOH M, Cassell A, Niang L, Rebbeck T, et al
    Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16178.
    PubMed     Abstract available


  87. PATTENDEN TA, Thangasamy IA, Ong WL, Samaranayke D, et al
    Barriers and enablers of active surveillance for prostate cancer - a qualitive study of clinicians.
    BJU Int. 2023 Sep 11. doi: 10.1111/bju.16176.
    PubMed     Abstract available


  88. KHANNA Y, Chinni V, Gnanasambantham K, O'Sullivan R, et al
    Can (68) Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?
    BJU Int. 2023;132:321-328.
    PubMed     Abstract available


    August 2023
  89. BODAR YJL, Boeve LMS, van Leeuwen PJ, Baars PC, et al
    Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer.
    BJU Int. 2023 Aug 24. doi: 10.1111/bju.16167.
    PubMed     Abstract available


  90. DAVIK P, Remmers S, Elschot M, Roobol MJ, et al
    Performance of MRI-based Prostate Cancer Risk Calculators and decision strategies in two large European medical centres.
    BJU Int. 2023 Aug 22. doi: 10.1111/bju.16163.
    PubMed     Abstract available


  91. BERNARDINO R, Sayyid RK, Leao R, Zlotta AR, et al
    Increasing Trends of Utilizing Active Surveillance for Gleason 7 (3+4) Prostate Cancer.
    BJU Int. 2023 Aug 22. doi: 10.1111/bju.16162.
    PubMed    


  92. SOLANKI AA, Yoo RK, Adams W, Davicioni E, et al
    F-SHARP: A Phase I/II Trial of Focal Salvage HDR Brachytherapy for Radiorecurrent Prostate Cancer.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16150.
    PubMed     Abstract available


  93. LAUGHLIN BS, Anderson JD, Hobbis D, Armstrong M, et al
    Energy Use in Moderate Hypofractionation and Stereotactic Body Radiotherapy for Prostate Cancer.
    BJU Int. 2023 Aug 8. doi: 10.1111/bju.16151.
    PubMed    


  94. FURRER MA, Sathianathen N, Gahl B, Corcoran NM, et al
    Oncological outcomes after attempted nerve sparing radical prostatectomy in patients with high-risk prostate cancer are comparable to standard non-nerve sparing radical prostatectomy: a longitudinal long-term propensity-matched single-centre study.
    BJU Int. 2023 Aug 7. doi: 10.1111/bju.16126.
    PubMed     Abstract available



  95. AUA and SUO publish guideline regarding early detection of prostate cancer | Hormone treatment for biochemical recurrence following definitive therapy of prostate cancer | World-famous surgical museum reopens following multimillion pound renovation.
    BJU Int. 2023;132:120-121.
    PubMed    


    July 2023
  96. ALTERBECK M, Thimansson E, Bengtsson J, Baubeta E, et al
    A pilot study of an organised population-based testing programme for prostate cancer.
    BJU Int. 2023 Jul 31. doi: 10.1111/bju.16143.
    PubMed     Abstract available


  97. CHEN K, Ong S, Vasundhara K, Mun CK, et al
    Is Genetic testing coming of age in advanced prostate cancer?
    BJU Int. 2023 Jul 27. doi: 10.1111/bju.16139.
    PubMed    


  98. SAYYID RK, Klaassen Z, Berlin A, Roy S, et al
    Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
    BJU Int. 2023 Jul 17. doi: 10.1111/bju.16130.
    PubMed     Abstract available


  99. SAYYID RK, Bernardino R, Al-Daqqaq Z, Tiwari R, et al
    Mesorectal Nodal Metastasis with Seminal Vesicle Invasion in Biochemically Recurrent Prostate Cancer.
    BJU Int. 2023 Jul 11. doi: 10.1111/bju.16123.
    PubMed     Abstract available


  100. MASSIE C, Gnanapragasam VJ, Barrett T, Warren A, et al
    Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.
    BJU Int. 2023 Jul 10. doi: 10.1111/bju.16101.
    PubMed    


  101. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
    BJU Int. 2023 Jul 8. doi: 10.1111/bju.16122.
    PubMed     Abstract available


  102. DE PABLOS-RODRIGUEZ P, Claps F, Rebez G, Crespo NV, et al
    Personalized Indocyanine-guided lymphadenectomy for prostate cancer. A randomized Clinical Trial.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16117.
    PubMed     Abstract available


  103. CUSSENOT O, Cancel-Tassin G, Rao SR, Woodcock DJ, et al
    Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16120.
    PubMed     Abstract available


  104. YANAGISAWA T, Kawada T, Mori K, Shim SR, et al
    Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
    BJU Int. 2023 Jul 3. doi: 10.1111/bju.16106.
    PubMed     Abstract available



  105. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    PubMed    


  106. HILL GT, Jeyanthi M, Coomer W, Bryant RJ, et al
    Same-day discharge robot-assisted laparoscopic prostatectomy: feasibility, safety and patient experience.
    BJU Int. 2023;132:92-99.
    PubMed     Abstract available


    June 2023
  107. LIGHT A, Peters M, Reddy D, Kanthabalan A, et al
    External validation of a risk model predicting failure of salvage focal ablation for prostate cancer.
    BJU Int. 2023 Jun 29. doi: 10.1111/bju.16102.
    PubMed     Abstract available


  108. JAIN A, Nassour AJ, Symons JL, Chung A, et al
    The effect of different assays on prostate-specific antigen testing.
    BJU Int. 2023;131:689-691.
    PubMed    


  109. KANEKO M, Medina LG, Lenon MSL, Sayegh AS, et al
    Transperineal magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy under local anaesthesia: the 'double-freehand' technique.
    BJU Int. 2023;131:770-774.
    PubMed    


  110. BRYANT RJ, Yamamoto H, Eddy B, Kommu S, et al
    Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique.
    BJU Int. 2023;131:694-704.
    PubMed     Abstract available


  111. JIA Z, Chen Z, Chang Y, Wu C, et al
    Sustainable functional urethral reconstruction improves early urinary continence after robot-assisted radical prostatectomy: a randomised controlled trial.
    BJU Int. 2023;131:720-728.
    PubMed     Abstract available


  112. FAINBERG J
    Focal therapy using irreversible electroporation: reported successes, with clear limitations, in both primary and salvage settings.
    BJU Int. 2023;131 Suppl 4:34-35.
    PubMed    


  113. BRANT A, Campi R, Carrion DM, Esperto F, et al
    Findings from an international survey of urology trainee experience with prostate biopsy.
    BJU Int. 2023;131:705-711.
    PubMed     Abstract available


    May 2023
  114. LIGHT A, Sarphie DF, Mian R, Li X, et al
    The Leukocyte ImmunoTest for identifying radiorecurrent prostate cancer: a pilot study.
    BJU Int. 2023 May 11. doi: 10.1111/bju.16043.
    PubMed    



  115. Issues related to prostate cancer management.
    BJU Int. 2023;131:518-519.
    PubMed    


  116. MEISSNER VH, Simson BW, Dinkel A, Schiele S, et al
    Treatment decision regret in long-term survivors after radical prostatectomy: a longitudinal study.
    BJU Int. 2023;131:623-630.
    PubMed     Abstract available


    April 2023
  117. WEI G, Ranasinghe W, Evans M, Bolton D, et al
    Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry.
    BJU Int. 2023 Apr 26. doi: 10.1111/bju.15980.
    PubMed     Abstract available


  118. CASTELLO A, Rodriguez-Barranco M, Perez-Gomez B, Chirlaque MD, et al
    High adherence to Western dietary pattern and prostate cancer risk: findings from the EPIC-Spain cohort.
    BJU Int. 2023 Apr 19. doi: 10.1111/bju.16001.
    PubMed     Abstract available


  119. ANDRING LM, Abu-Gheida I, Bathala T, Yoder AK, et al
    Definitive local therapy for T4 prostate cancer associated with improved local control and survival.
    BJU Int. 2023 Apr 14. doi: 10.1111/bju.16027.
    PubMed     Abstract available


  120. LOPEZ JF, Bryant RJ
    The 'Rapid Access Prostate Imaging and Diagnosis' (RAPID) diagnostic pathway: what is the rush?
    BJU Int. 2023;131:377-379.
    PubMed    


  121. KANAGARAJAH A, Hogan D, Yao HH, Dundee P, et al
    A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy.
    BJU Int. 2023;131:408-423.
    PubMed     Abstract available


  122. SHORE ND, Stenzl A, Pieczonka C, Klaassen Z, et al
    Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
    BJU Int. 2023;131:452-460.
    PubMed     Abstract available


    March 2023
  123. LAZZERI M, Fasulo V, Tinterri C
    Eve's and Adam's rib for prostate cancer screening.
    BJU Int. 2023 Mar 15. doi: 10.1111/bju.15999.
    PubMed    


  124. YAXLEY JW
    Focal irreversible electroporation for treatment of primary and radio-recurrent prostate cancer - the evidence is mounting!
    BJU Int. 2023 Mar 6. doi: 10.1111/bju.15987.
    PubMed    



  125. Prostate-specific antigen for prostate cancer screening.
    BJU Int. 2023;131:266.
    PubMed    


  126. MOROTE J, Pye H, Campistol M, Celma A, et al
    Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
    BJU Int. 2023 Mar 1. doi: 10.1111/bju.15998.
    PubMed     Abstract available


    February 2023
  127. STROOMBERG HV, Andersen MCM, Helgstrand JT, Larsen SB, et al
    Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result.
    BJU Int. 2023 Feb 27. doi: 10.1111/bju.15997.
    PubMed     Abstract available


  128. MA TM, Czernin J, Felix C, Alano R, et al
    LUNAR: a randomized phase 2 study of (177) Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol).
    BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988.
    PubMed     Abstract available


  129. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    BJU Int. 2023;131:227-235.
    PubMed     Abstract available


    January 2023
  130. VICKERS A
    Do not treat Bill Gates for prostate cancer! Algorithmic bias and causality in medical prediction.
    BJU Int. 2023 Jan 30. doi: 10.1111/bju.15951.
    PubMed    


  131. CUSSENOT O, Renard-Penna R, Montagne S, Ondet V, et al
    Clinical performance of MRI & biomarkers for prostate cancer diagnosis in men at high genetic risk.
    BJU Int. 2023 Jan 17. doi: 10.1111/bju.15968.
    PubMed     Abstract available


  132. GEBOERS B, Scheltema MJ, Blazevski A, Katelaris A, et al
    Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    BJU Int. 2023 Jan 3. doi: 10.1111/bju.15948.
    PubMed     Abstract available


    December 2022
  133. HANSEN RS, Biorn SH, Birk-Korch JB, Sheikh SP, et al
    Prevalence of prostate cancer in men with haematuria: A systematic review and meta-analysis.
    BJU Int. 2022 Dec 15. doi: 10.1111/bju.15950.
    PubMed     Abstract available


  134. BLAZEVSKI A, Geboers B, Scheltema MJ, Gondoputro W, et al
    Salvage irreversible electroporation for radio recurrent prostate cancer - The prospective FIRE trial.
    BJU Int. 2022 Dec 10. doi: 10.1111/bju.15947.
    PubMed     Abstract available


  135. SCHELTEMA MJ, Geboers B, Blazevski A, Doan P, et al
    Median 5-year outcomes of primary focal irreversible electroporation for localized prostate cancer.
    BJU Int. 2022 Dec 10. doi: 10.1111/bju.15946.
    PubMed     Abstract available


  136. KOSTER KL, Zumstein V, Suveg K, Jochum W, et al
    Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
    BJU Int. 2022 Dec 5. doi: 10.1111/bju.15847.
    PubMed    


  137. BASS EJ, Ahmed HU
    Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3.
    BJU Int. 2022 Dec 5. doi: 10.1111/bju.15859.
    PubMed    


  138. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    PubMed     Abstract available


    November 2022
  139. HOGENHOUT R, Osses DF, Alberts AR, Buizer-Rijksen HG, et al
    Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
    BJU Int. 2022 Nov 21. doi: 10.1111/bju.15933.
    PubMed     Abstract available


  140. KELLY R, Jensen A, Karunaratna N, Wong S, et al
    PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC).
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15930.
    PubMed    


  141. DOAN P, Counter W, Papa N, Sheehan-Dare G, et al
    Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer.
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15929.
    PubMed     Abstract available


  142. CUSSENOT O, Cancel-Tassin G, Comperat E, Benbouzid S, et al
    Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?
    BJU Int. 2022;130:582-585.
    PubMed    


  143. VAN DER SLOT MA, den Bakker MA, Tan TSC, Remmers S, et al
    NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
    BJU Int. 2022;130:628-636.
    PubMed     Abstract available


  144. LAWRENTSCHUK N
    Funding of all issues related to prostate cancer treatment should be a priority and have equal access - a key to survivorship.
    BJU Int. 2022;130 Suppl 3:4.
    PubMed    


  145. YAXLEY WJ, Mackean J, Desai DJ, Tsang G, et al
    Oncological and urinary outcomes following low-dose-rate brachytherapy with a median follow-up of 11.8 years.
    BJU Int. 2022;130 Suppl 3:40-45.
    PubMed     Abstract available


  146. ROBERTS MJ, Chatfield MD, Hruby G, Nandurkar R, et al
    Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    BJU Int. 2022;130 Suppl 3:32-39.
    PubMed     Abstract available


    September 2022
  147. ELDRED-EVANS D, Connor MJ, Bertoncelli Tanaka M, Bass E, et al
    The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) prostate cancer diagnostic pathway.
    BJU Int. 2022 Sep 22. doi: 10.1111/bju.15899.
    PubMed     Abstract available


  148. VEERMAN H, Donswijk M, Bekers E, Bodar YJL, et al
    The Oncological Characteristics of Non-PSMA-Expressing Primary Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2022 Sep 19. doi: 10.1111/bju.15896.
    PubMed    


  149. EHRET F, Hofmann T, Furweger C, Kufeld M, et al
    Single-fraction PSMA-PET- and multiparametric MRI-guided SBRT for Prostate Cancer Local Recurrences.
    BJU Int. 2022 Sep 17. doi: 10.1111/bju.15894.
    PubMed     Abstract available


  150. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or coexistence?
    BJU Int. 2022 Sep 12. doi: 10.1111/bju.15074.
    PubMed    


  151. ORRASON AW, Styrke J, Garmo H, Stattin P, et al
    Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.
    BJU Int. 2022 Sep 11. doi: 10.1111/bju.15891.
    PubMed     Abstract available


  152. ICZKOWSKI KA, Molina M, Egevad L, Bostwick DG, et al
    Low-Grade Prostate Cancer Should Still be Labeled Cancer.
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15886.
    PubMed    


  153. ONG S, Chen K, Grummet J, Yaxley J, et al
    Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus?
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15883.
    PubMed     Abstract available


  154. MEIJER D, Ettema RH, van Leeuwen PJ, van der Kwast TH, et al
    The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
    BJU Int. 2022 Sep 7. doi: 10.1111/bju.15881.
    PubMed     Abstract available



  155. Updates on bladder, kidney and prostate cancers.
    BJU Int. 2022;130:275-276.
    PubMed    


  156. RAHOTA RG, Salin A, Gautier JR, Almeras C, et al
    A prehabilitation programme implemented before robot-assisted radical prostatectomy improves peri-operative outcomes and continence recovery.
    BJU Int. 2022;130:357-363.
    PubMed     Abstract available


    August 2022
  157. EXTERKATE L, Wegelin O, Barentsz JO, van der Leest MG, et al
    Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
    BJU Int. 2022 Aug 22. doi: 10.1111/bju.15876.
    PubMed     Abstract available


  158. SCHNEIDER A, Bulafka J, Arisi MF, Li L, et al
    Case of the month from the Thomas Jefferson Sidney Kimmel medical college, Philadelphia, USA. Prostatic abscess and advanced prostate cancer: considering malignancy in the differential diagnosis.
    BJU Int. 2022;130:181-185.
    PubMed    


    July 2022
  159. WILLIAMS IS, Perera S, Murphy DG, Corcoran NM, et al
    Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?
    BJU Int. 2022 Jul 25. doi: 10.1111/bju.15860.
    PubMed    


  160. RUSHWORTH LK, Loveridge C, Salji M, MacLeod M, et al
    Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer.
    BJU Int. 2022 Jul 18. doi: 10.1111/bju.15851.
    PubMed     Abstract available



  161. FDA approves new agent for the treatment of metastatic prostate cancer.
    BJU Int. 2022;130:3-4.
    PubMed    


  162. PARRY MG, Skolarus TA, Nossiter J, Sujenthiran A, et al
    Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes.
    BJU Int. 2022;130:84-91.
    PubMed     Abstract available


  163. SETIA SA, Smith J, Cendo D, Yoder J, et al
    Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
    BJU Int. 2022;130:54-61.
    PubMed     Abstract available


    June 2022
  164. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
    Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
    BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
    PubMed     Abstract available


  165. AGGARWAL A, Han L, Tree A, Lewis D, et al
    Impact of centralisation of prostate cancer services on the choice of radical treatment.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15830.
    PubMed     Abstract available


  166. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
    How and when should radiologists report T-staging on MRI in patients with prostate cancer?
    BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.
    PubMed    


  167. HARVEY M, Ong WL, Chao M, Udovicich C, et al
    Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
    BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
    PubMed     Abstract available


  168. LANGLEY S, Eden C, Perry M, Patil K, et al
    Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
    BJU Int. 2022;129:731-736.
    PubMed     Abstract available


  169. LAWRENTSCHUK N
    Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
    BJU Int. 2022;130 Suppl 1:4.
    PubMed    


  170. PERRY E, Talwar A, Taubman K, Ng M, et al
    Pathological predictors of (18) F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
    BJU Int. 2022;130 Suppl 1:28-36.
    PubMed     Abstract available


    May 2022
  171. O'BRIEN JS, McVey A, Kelly BD, Jenjitranant P, et al
    PSMA PET-CT Funding Grants Free Access to Superior Staging for Australian Men with Prostate Cancer.
    BJU Int. 2022 May 16. doi: 10.1111/bju.15773.
    PubMed    


  172. RAHOTA RG, Diamand R, Malavaud B, Fiard G, et al
    Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    BJU Int. 2022;129:621-626.
    PubMed     Abstract available


  173. HAYNE D, Grummet J, Espinoza D, McCombie SP, et al
    'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
    BJU Int. 2022;129:591-600.
    PubMed     Abstract available


    April 2022
  174. NATHAN A, Morris M, Parry MG, Berry B, et al
    Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15766.
    PubMed     Abstract available


  175. VAN RIEL LAMJG, Geboers B, Kabaktepe E, Blazevski A, et al
    Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15759.
    PubMed     Abstract available


  176. BOKU H, Kaneko M, Yamada Y, Morinaga Y, et al
    Microwave for focal therapy of prostate cancer: Non-clinical study and exploratory clinical trial.
    BJU Int. 2022 Apr 18. doi: 10.1111/bju.15749.
    PubMed     Abstract available


  177. LANE JA, Donovan JL, Young GJ, Davis M, et al
    Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study).
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15739.
    PubMed     Abstract available


  178. CHASE EC, Bryant AK, Sun Y, Jackson WC, et al
    Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients.
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15740.
    PubMed     Abstract available


  179. PTASZNIK G, Papa N, Kelly BD, Thompson J, et al
    High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer.
    BJU Int. 2022 Apr 1. doi: 10.1111/bju.15736.
    PubMed    



  180. Prostate cancer and ethnicity, personalised treatment for renal masses and oral testosterone for hypogonadism.
    BJU Int. 2022;129:422.
    PubMed    


  181. LUZZAGO S, Piccinelli ML, Mistretta FA, Bianchi R, et al
    Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
    BJU Int. 2022;129:524-533.
    PubMed     Abstract available


    March 2022

  182. New guidance regarding the diagnosis and risk stratification of patients with prostate cancer.
    BJU Int. 2022;129:304-305.
    PubMed    


  183. KLEIN RJ
    Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
    BJU Int. 2022;129:271.
    PubMed    


  184. FERRARO S, Biganzoli EM
    Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.
    BJU Int. 2022;129:418.
    PubMed    


  185. MARTIN RM, Dixon P, Turner E, Keeney E, et al
    Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.
    BJU Int. 2022;129:269-270.
    PubMed    


  186. TEYATEETI A, Grossman C, Kollmeier MA, Fiasconaro M, et al
    Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.
    BJU Int. 2022;129:337-344.
    PubMed     Abstract available


  187. BJORKLUND J, Stattin P, Ronmark E, Aly M, et al
    The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study.
    BJU Int. 2022;129:318-324.
    PubMed     Abstract available


  188. ZHAO J, Sun G, Zhu S, Dai J, et al
    Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    BJU Int. 2022;129:345-355.
    PubMed     Abstract available


  189. PASCHEN U, Sturtz S, Fleer D, Lampert U, et al
    Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    BJU Int. 2022;129:280-289.
    PubMed     Abstract available


    February 2022
  190. BODAR YJL, Veerman H, Meijer D, de Bie K, et al
    Standardised Uptake Values as Determined on PSMA PET/CT is associated with Oncological Outcomes in Prostate Cancer Patients.
    BJU Int. 2022 Feb 15. doi: 10.1111/bju.15710.
    PubMed     Abstract available


  191. DASON S, Vertosick EA, Udo K, Sjoberg DD, et al
    Clinical utility of subclassifying positive surgical margins at radical prostatectomy.
    BJU Int. 2022;129:194-200.
    PubMed     Abstract available


  192. SORCE G, Stabile A, Luciano R, Motterle G, et al
    Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
    BJU Int. 2022;129:201-207.
    PubMed     Abstract available


    January 2022
  193. NOSSITER J, Morris M, Parry MG, Sujenthiran A, et al
    Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15699.
    PubMed     Abstract available


  194. ONG WL, Thangasamy I, Murphy D, Pritchard E, et al
    Large variation in conservative management for low-risk prostate cancer in Australia and New Zealand.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15698.
    PubMed    


  195. BRATT O
    Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making.
    BJU Int. 2022;129:3-4.
    PubMed    


  196. GRAY WK, Day J, Briggs TWR, Harrison S, et al
    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
    BJU Int. 2022;129:93-103.
    PubMed     Abstract available


    December 2021
  197. RANNIKKO A, Leht M, Mirtti T, Kenttamies A, et al
    Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.
    BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
    PubMed     Abstract available


  198. SOORIAKUMARAN P, Wilson C, Rombach I, Hassanali N, et al
    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial.
    BJU Int. 2021 Dec 8. doi: 10.1111/bju.15669.
    PubMed     Abstract available


  199. VEERMAN H, Donswijk M, Bekers E, Olde Heuvel J, et al
    Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15664.
    PubMed     Abstract available



  200. Acute Urinary Retention and Cancer; Is It All About the Prostate?
    BJU Int. 2021;128:660.
    PubMed    


  201. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
    Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
    BJU Int. 2021;128:688-691.
    PubMed    


  202. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
    Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    BJU Int. 2021;128:702-712.
    PubMed     Abstract available


  203. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
    The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
    BJU Int. 2021;128 Suppl 3:45-51.
    PubMed     Abstract available


    November 2021
  204. JOHN JB, Pascoe J, Fowler S, Walton T, et al
    A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15656.
    PubMed     Abstract available


  205. ROSENBERG JE, Jung JH, Lee H, Lee S, et al
    Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer: a Cochrane Review.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15657.
    PubMed     Abstract available


  206. LEE V, An Y, Park HS, Yu JB, et al
    Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History.
    BJU Int. 2021 Nov 22. doi: 10.1111/bju.15650.
    PubMed     Abstract available


  207. KANNAN A, Clouston D, Frydenberg M, Ilic D, et al
    Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis.
    BJU Int. 2021 Nov 16. doi: 10.1111/bju.15647.
    PubMed     Abstract available


  208. HOFBAUER SL, Luger F, Harland N, Plage H, et al
    A Non-Inferiority Comparative Analysis of Micro-Ultrasound and MRI Targeted Biopsy in Men at Risk of Prostate Cancer.
    BJU Int. 2021 Nov 13. doi: 10.1111/bju.15635.
    PubMed     Abstract available


  209. IP CCK, Kealey J, Davis ID, Sengupta S, et al
    Impacts of the COVID-19 Pandemic on Early Detection of Prostate Cancer in Australia.
    BJU Int. 2021 Nov 9. doi: 10.1111/bju.15631.
    PubMed     Abstract available


  210. HEESTERMAN BL, van der Poel HG, Schoots IG, Mehra N, et al
    Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    BJU Int. 2021 Nov 6. doi: 10.1111/bju.15632.
    PubMed     Abstract available


  211. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
    Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
    BJU Int. 2021;128:555-557.
    PubMed    


  212. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
    Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    BJU Int. 2021;128:598-606.
    PubMed     Abstract available


  213. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
    Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
    BJU Int. 2021;128:615-624.
    PubMed     Abstract available


    October 2021
  214. HUYNH LM, Huang E, Towe M, Liang K, et al
    Evidence for integration of total and free testosterone levels in management of prostate cancer.
    BJU Int. 2021 Oct 30. doi: 10.1111/bju.15626.
    PubMed     Abstract available


  215. POULIOT F, Beauregard JM, Saad F, Trudel D, et al
    The 3TMPO study protocol: triple-tracer PET imaging of metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15621.
    PubMed     Abstract available


  216. WITT JH, Friedrich M, Jandrig B, Porsch M, et al
    Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
    BJU Int. 2021 Oct 17. doi: 10.1111/bju.15618.
    PubMed     Abstract available


  217. MARRA G, Calleris G, Marquis A, Oderda M, et al
    Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:524.
    PubMed    


  218. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
    Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:523.
    PubMed    


  219. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
    'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
    BJU Int. 2021;128:428-430.
    PubMed    


  220. KELLY R, Anton A, Wong S, Shapiro J, et al
    Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
    BJU Int. 2021;128 Suppl 1:18-26.
    PubMed     Abstract available


  221. CATHCART P, Ribeiro L, Moore C, Ahmed HU, et al
    Outcomes of the RAFT trial: robotic surgery after focal therapy.
    BJU Int. 2021;128:504-510.
    PubMed     Abstract available


    September 2021
  222. LIGHT A, Burns-Cox N, Maccormick A, John J, et al
    The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.
    BJU Int. 2021;128:298-300.
    PubMed    


    August 2021
  223. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
    Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
    PubMed     Abstract available


  224. MOROTE J, Schwartzmann I, Celma A, Roche S, et al
    The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
    BJU Int. 2021 Aug 10. doi: 10.1111/bju.15568.
    PubMed     Abstract available


  225. DOAN P, Graham P, Lahoud J, Remmers S, et al
    A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
    PubMed     Abstract available


  226. ISRAEL B, Immerzeel J, van der Leest M, Hannink G, et al
    Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer.
    BJU Int. 2021 Aug 6. doi: 10.1111/bju.15562.
    PubMed     Abstract available



  227. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
    BJU Int. 2021;128:127-130.
    PubMed    


  228. DUDDERIDGE TJ
    Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.
    BJU Int. 2021;128:125-126.
    PubMed    


  229. INOUE T, Sasaki T, Kato M, Masui S, et al
    Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    BJU Int. 2021 Aug 1. doi: 10.1111/bju.15561.
    PubMed     Abstract available



  230. Chemotherapeutic treatment of MCRPC and non-MCRPC.
    BJU Int. 2021;128:153-154.
    PubMed    


  231. TAMIR S, Hermann D, Margel D, Gavrielli S, et al
    Indications for prostate multiparametric magnetic resonance imaging: changes over 7 years in a single referral centre.
    BJU Int. 2021;128:165-167.
    PubMed    


    July 2021
  232. BUELENS S, Poelaert F, Claeys T, De Bleser E, et al
    Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study.
    BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553.
    PubMed     Abstract available


  233. KAMRAN SC, Zietman AL
    Radiation Treatment in Prostate Cancer: Covering the Waterfront.
    BJU Int. 2021 Jul 17. doi: 10.1111/bju.15550.
    PubMed     Abstract available


  234. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
    Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
    PubMed     Abstract available


  235. BENAFIF S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al
    The BARCODE1 Pilot: a feasibility study of using germline SNPs to target prostate cancer screening.
    BJU Int. 2021 Jul 2. doi: 10.1111/bju.15535.
    PubMed     Abstract available


  236. MOTTRIE A, Mazzone E, Wiklund P, Graefen M, et al
    Objective assessment of intraoperative skills for robot-assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative.
    BJU Int. 2021;128:103-111.
    PubMed     Abstract available


  237. SINGH S, Sandhu P, Beckmann K, Santaolalla A, et al
    Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    BJU Int. 2021;128:72-78.
    PubMed     Abstract available


    June 2021
  238. MORI K, Mostafaei H, Sari Motlagh R, Pradere B, et al
    Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis.
    BJU Int. 2021 Jun 25. doi: 10.1111/bju.15507.
    PubMed     Abstract available


  239. BERTONCELLI TANAKA M, Sahota K, Burn J, Falconer A, et al
    Prostate cancer in transgender women: what does a urologist need to know?
    BJU Int. 2021 Jun 22. doi: 10.1111/bju.15521.
    PubMed     Abstract available


  240. ALBERTSEN P
    Prostate cancer: the interplay between genetics and the environment.
    BJU Int. 2021;127:615-616.
    PubMed    


  241. YAXLEY J
    Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
    BJU Int. 2021;127:747.
    PubMed    


  242. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    PubMed    


  243. TANDOGDU Z, Collins J, Shaw G, Rohn J, et al
    Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
    BJU Int. 2021;127:729-741.
    PubMed     Abstract available


  244. DINNEEN E, Haider A, Grierson J, Freeman A, et al
    NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial.
    BJU Int. 2021;127:676-686.
    PubMed     Abstract available


    May 2021
  245. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
    ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
    PubMed     Abstract available


  246. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
    Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
    PubMed     Abstract available


  247. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
    Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
    BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
    PubMed     Abstract available


  248. O'CALLAGHAN M, Papa N, Pase M, Frydenberg M, et al
    Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?
    BJU Int. 2021 May 11. doi: 10.1111/bju.15366.
    PubMed    



  249. Recent advances in the diagnosis and management of prostate cancer.
    BJU Int. 2021;127:518-519.
    PubMed    


  250. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
    Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2021;127:524-527.
    PubMed    


  251. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
    Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2021;127:560-566.
    PubMed     Abstract available


  252. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
    A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
    BJU Int. 2021;127:575-584.
    PubMed     Abstract available


  253. TIMM B, Farag M, Liodakis P, Angus D, et al
    Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    BJU Int. 2021;127 Suppl 1:23-29.
    PubMed     Abstract available


  254. JOHN A, John H, Catterwell R, Selth LA, et al
    Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis.
    BJU Int. 2021;127 Suppl 1:13-22.
    PubMed     Abstract available


    April 2021
  255. CHILUKURI S, Murthy V
    Adjuvant radiation for prostate cancer: Too early to abandon?
    BJU Int. 2021 Apr 9. doi: 10.1111/bju.15422.
    PubMed     Abstract available


  256. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.
    BJU Int. 2021 Apr 3. doi: 10.1111/bju.15417.
    PubMed     Abstract available


  257. XU AJ, Taylor J, Gao T, Mihalcea R, et al
    TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.
    BJU Int. 2021 Apr 2. doi: 10.1111/bju.15403.
    PubMed     Abstract available


  258. GALFANO A, Secco S, Dell'Oglio P, Rha K, et al
    Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents.
    BJU Int. 2021;127:412-417.
    PubMed     Abstract available


    March 2021
  259. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
    Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
    BJU Int. 2021;127:304-306.
    PubMed    


  260. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
    Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
    BJU Int. 2021;127:361-368.
    PubMed     Abstract available


    February 2021
  261. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
    Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
    BJU Int. 2021;127:190-197.
    PubMed     Abstract available


    January 2021
  262. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
    'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
    BJU Int. 2021;127:37-40.
    PubMed    



  263. World News.
    BJU Int. 2021;127:1-3.
    PubMed    


  264. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
    Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
    BJU Int. 2021;127:114-121.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.